key: cord-0742996-96rezn56 authors: Doms, J.; Prior, J.O.; Peters, S.; Obeid, M. title: Tocilizumab for refractory severe immune checkpoint inhibitor–associated myocarditis date: 2020-05-16 journal: Ann Oncol DOI: 10.1016/j.annonc.2020.05.005 sha: 2e5e4ef80df70479c84d5a62f7e0e88eafa6f016 doc_id: 742996 cord_uid: 96rezn56 nan Immune-checkpoint inhibitors Corticosteroids were progressively tapered and the patient did not experience any recurrence of cardiac or myositis adverse events. The immunotherapy was discontinued. Severe and refractory immune checkpoint inhibitor-related myocarditis represents an important clinical challenge due to its high mortality, despite the use of immunosuppression escalation and the availability of multiple immunosuppressant drugs (IS) such as infliximab, rituximab, tacrolimus, antithymocyte globulin, MMF or tacrolimus. The successful use of abatacept 2 and alemtuzumab 3 , two selective IS, has been recently reported for this condition. Interleukin (IL)-6 is a critical driver of acute and chronic inflammation. During inflammation, IL-6 signaling drives T cell survival, expansion and proliferation. 4 Moreover, IL-6 signaling promotes a pro-tumorigenic immune-suppressive network. 5 Compared to the other available selective IS, the anti-IL-6R agent TCZ offers several strategic advantages without the risk of compromising immune checkpoint inhibitor efficacy. 6 In addition, it carries complementary anti-tumor properties, because IL-6 blockade significantly improves the differentiation of CD4 + T cells into IFN-γ-producing effector Th1 cells. 7 Furthermore, accumulating evidence suggests that the IL-6-Th-17 pathway may have an important role in the pathogenesis of irAEs, especially in steroid-refractory cases. 8, 9 IL-17A-expressing CD4 + T cells (c-Kit − CD161 + MDR1 + Th17 cells) have been reported as key effectors of autoimmune inflammation refractory to glucocorticoids. 8 The pathogenic effect of IL-6 is essential in the differentiation of pro-inflammatory Th-17 cells from naïve CD4 + T cells, which might suggest a role for this Th17 subset in steroid-refractory irAEs. 10 Another important report showed that among adults receiving chimeric antigen receptor T cells, early administration of TCZ to treat the cytokine release syndrome was associated with a lower rate of cardiovascular events. 11 Recently, an approach of blocking the IL-6/IL-6R axis using TCZ suggested a promising immuno-modulatory therapeutic strategy and could be beneficial to avoid rapid clinical deterioration from severe forms of COVID-19. 12 Very interestingly, what we have noticed in our fragile patient is that he remained pauci-symptomatic despite having become COVID-19 positive during long immunosuppression. This observation could suggest a possible additional beneficial effect for TCZ on the clinical courseCOVID-19. In our patient, the use of tocilizumab led to the rapid resolution of the refractory high-grade myocarditis, allowing a significant reduction in the total duration of immunosuppression. The patient began receiving methylprednisolone sodium succinate at a dose of 1 g daily for one day, followed by a dose of 200 mg daily with initial improvement of biochemical variables. Despite receiving high doses of methylprednisolone, the patient had an immune flare associated with rapid increase in ferritin and troponin T. Tocilizumab at a dose of 8 mg/kg was administrated at day 7 and 14. This allowed for troponin T and I, CK, ferritin levels and inflammatory parameters to rapidly decrease and was associated with the resolution of the myocarditis and myositis, according to clinical and biochemical measures. The patient was then progressively weaned from corticosteroids and did not experience any recurrence of cardiac, myositis or HPS adverse events. ‡ High-sensitivity troponin T is expressed by skeletal muscle, including regenerating skeletal muscle tissue whereas highsensitivity troponin I is specific to the myocardium. 3, 13 As reported before 3 , given that the patient had severe myositis related to immunotherapy, the high-sensitivity troponin T concentration reflected active skeletal muscle regeneration rather than active myocarditis in the context of normalization of the high-sensitivity troponin I concentration and creatine kinase level. 3 CK, creatine kinase; d, day ; hs, high-sensitivity; IV, intravenous; MP, methylprednisolone sodium succinate pulse; PDN, prednisone; TCZ, tocilizumab; ; us, ultra-sensitivity ; MO received a fund from the Leenaards foundation. MO conceived of and wrote the manuscript, and prepared the figures. All authors wrote, commented on, and corrected the manuscript. All authors read and approved the final version of the manuscript. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy IL-6 Promotes T Cell Proliferation and Expansion under Inflammatory Conditions in Association with Low-Level RORgammat Expression Immune-suppressive effects of interleukin-6 on T-cell-mediated anti-tumor immunity IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer Lack of interleukin-6 in the tumor microenvironment augments type-1 immunity and increases the efficacy of cancer immunotherapy Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T) Effective Treatment of Severe COVID-19 Patients with Tocilizumab Cardiac troponin testing in idiopathic inflammatory myopathies and systemic sclerosis-spectrum disorders: biomarkers to distinguish between primary cardiac involvement and low-grade skeletal muscle disease activity